Lwin Bo B, Vashishta Apoorva, Nishat Samreen, Mueka Isaac N, Hassan Maria U, Pandey Ravi K, Almansouri Naiela E
Clinical Research, California Institute of Behavioral Neurosciences and Psychology (CIBNP), Fairfield, USA.
Clinical Research, NewYork-Presbyterian Queens, New York, USA.
Cureus. 2024 Aug 7;16(8):e66361. doi: 10.7759/cureus.66361. eCollection 2024 Aug.
Genetic variations among people mainly determine the blood levels of lipoprotein (a) (Lp(a)), and it is relatively stable throughout one's lifetime. Nevertheless, there could still be other factors that control the Lp(a) level. Thyroid hormones are known to influence the serum lipid level by regulating the expression of key enzymes that are involved in lipid metabolism. Both hypo and hyperthyroidism are associated with changes in lipid levels. Even though thyroid hormone abnormalities have been shown to alter traditional lipid parameters like low-density lipoprotein (LDL-C), its influence on Lp(a) has not been established. This review aims to identify the relationship between Lp(a) and thyroid hormones by reviewing data from correlative studies and observing treatment-related Lp(a) level changes in thyroid disorders from interventional studies. We searched MEDLINE, Cochrane, and Google Scholar databases with predefined search criteria and search strategies for paper identification. Individual reviewers reviewed identified papers for selection. Finalized papers were reviewed for Lp(a) levels and their responses to treatment in patients with thyroid disorders to establish the relationship between Lp(a) and thyroid hormone. We concluded that the data were limited and sometimes contradicted one another to establish a clear relationship between Lp(a) and thyroid hormones. Even though correlative studies data showed strong indications that overt-hypothyroidism was associated with high Lp(a) levels, thyroid hormone replacement studies did not show any significant changes in Lp(a) levels compared to pre-treatment in patients with both overt-hypothyroidism and subclinical hypothyroidism. More clinical trials focusing on Lp(a) with longer periods of treatment and follow-up in thyroid patients are needed to establish the relationship between the two. The possibility of dose-related Lp(a) responses to thyroid hormone treatment should also be explored.
人与人之间的基因变异主要决定脂蛋白(a) [Lp(a)] 的血液水平,并且在人的一生中相对稳定。然而,仍可能存在其他控制Lp(a) 水平的因素。已知甲状腺激素通过调节参与脂质代谢的关键酶的表达来影响血清脂质水平。甲状腺功能减退和甲状腺功能亢进都与脂质水平的变化有关。尽管甲状腺激素异常已被证明会改变传统脂质参数,如低密度脂蛋白(LDL-C),但其对Lp(a) 的影响尚未明确。本综述旨在通过回顾相关研究的数据并观察干预研究中甲状腺疾病治疗相关的Lp(a) 水平变化,来确定Lp(a) 与甲状腺激素之间的关系。我们使用预定义的搜索标准和搜索策略在MEDLINE、Cochrane和谷歌学术数据库中进行检索以识别论文。由独立评审员对检索到的论文进行筛选。对最终选定的论文进行评估,分析甲状腺疾病患者的Lp(a) 水平及其对治疗的反应,以确定Lp(a) 与甲状腺激素之间的关系。我们得出结论,现有数据有限,且有时相互矛盾,难以明确Lp(a) 与甲状腺激素之间的关系。尽管相关研究数据有力地表明,显性甲状腺功能减退与高Lp(a) 水平相关,但甲状腺激素替代研究表明,显性甲状腺功能减退和亚临床甲状腺功能减退患者治疗后Lp(a) 水平与治疗前相比并无显著变化。需要更多针对甲状腺疾病患者、治疗周期和随访时间更长的聚焦于Lp(a) 的临床试验,以确定两者之间的关系。还应探索Lp(a) 对甲状腺激素治疗的剂量相关反应的可能性。